2026 PHARMA AND LIFE SCIENCES BENCHMARK REPORT
We Analyzed the Data Protection Posture of the 199 pharma & life sciences companies.
74% Sit in the "High" or "Critical" Risk Band.
We assessed 199 prominent pharma and life sciences firms across an 8-dimensional structural risk model. Download the report to benchmark your organization against the industry average of 39.6/40 and identify your specific vulnerabilities.
Pharma companies sell molecules, trial data, and the regulatory packages that turn them into one another. But our 2026 analysis reveals a structural threat to the Data Package: a widening gap between governed internal environments and unmanaged external workflows. Based exclusively on publicly available data — including therapeutic mix, CRO footprint, jurisdictional complexity, and AI adoption — this report explains why governance that stops at the sponsor's door is no longer governance at all.
Inside the report, you will find:
The 8-Dimension Exposure Index: See the methodology used to score 199 pharma, biotech, and CRO organizations.
The Chain of Custody Problem: Why every major clinical document platform loses governance the moment a file is exported
The Third-Party Blind Spot: How a single Phase III trial creates a data supply chain the sponsor cannot fully see or govern
The Shadow AI Reality: The unquantified risk behind the fact that 38% of sponsors are running confirmed AI tools, and why the disclosed number is the floor
A Financial Exposure Worksheet: The unquantified risk behind the fact that 38% of sponsors are running confirmed AI tools, and why the disclosed number is the floor